Publication
Case Report: triple therapy with pembrolizumab, ipilimumab, and lenvatinib in mitotane- and radiation-refractory, cortisol-secreting stage IV adrenocortical carcinoma: a genomically guided approach.
Authors not recorded
Front Immunol2026PMID 42158873PMC13180886stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260926-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerAdrenal Cortical Carcinomacivic_curation1.00
- drugIpilimumabcivic_curation1.00
- drugLenvatinibcivic_curation1.00
- drugPembrolizumabcivic_curation1.00
- variantHighcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-26
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 42158873
- Run
- ING-CIVIC-20260926-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| High1 | ||||||||
| Ipilimumab + Lenvatinib + PembrolizumabCombination | Adrenal Cortical CarcinomaALIAS | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID13303A 54-year-old female with recurrent stage IV ACC that progressed after adrenalectomy, radiation, and mitotane had a TMB-high (11.6 mutations/Mb), MSS, PD-L1-negative tumor with a markedly clonal molec… (full text at CIViC) PMID 42158873 · Nakhleh et al., 2026 · Open in CIViC | civic |